Business
Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity
Publication Highlights Impressive Weight Loss of Up to 14.7% from Baseline After 13 Weeks of Treatment; No Plateau Observed VK2735 Currently Being Evaluated
About this update from Viking Therapeutics, Inc.
[{"type":"text","content":"Publication Highlights Impressive Weight Loss of Up to 14.7% from Baseline After 13 Weeks of Treatment; No Plateau Observed VK2735 Currently Being Evaluated in VANQUISH Phase 3 Registrational Program in ObesitySAN DIEGO, Jan. 12, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the publication of the results of the company's Phase 2 VENTURE clinical trial of VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2375 is being developed in both oral and subcutaneous formulations for the potential treatment of various metabolic disorders such as obesity. \n \n \n \n \n \n \n \nThe paper, titled, \"Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study,\" was published in Obesity, the peer-reviewed journal of The Obesity Society. It can be accessed online at: https://onlinelibrary.wiley.com/doi/10.1002/oby.70106.The publication highlights the previously reported positive results from the Phase 2 VENTURE study of VK2735 in patients with obesity, which showed that the trial successfully achieved its primary and secondary endpoints. After 13 weekly subcutaneous doses, participants receiving VK2735 demonstrated statistically significant reductions in mean body weight from baseline, ranging up to 14.7% with no signs of plateau. VK2735 also demonstrated encouraging safety and tolerability in the VENTURE study, with the majority of observed adverse events (AEs) being reported as mild or moderate. Treatment and study discontinuation rates among VK2735 cohorts were well-balanced compared with placebo.\"We are happy to have the VENTURE Trial results published in the peer-reviewed journal of The Obesity Society, providing important visibility for these data across the medical community. The study data served to highlight the promise that VK2735 holds as a potentially best-in-class dual GLP-1/GIP agonist and were central to our designing of the ongoing VANQUISH Phase 3 program for VK2735,\" said Brian Lian Ph.D., chief executive officer of Viking. \"The response among patients and clinicians for the VANQUISH studies has been positive...